EUVIMEDEUVIMED entdecken
ValidierungsstudieKohortenstudieOpen Access · CC BY 4.0

Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation

Tetsu Hirakawa iD, Kakuhiro Yamaguchi iD, Shun Takao, Nobuhiro Kanaji, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto iD, Chihiro Ando, Hisao Higo iD, Masaaki Yanai, Koji Kurose, Yasunari Nagasaki und 13 weitere

Respirology · 2026

DOI: 10.1002/resp.70267 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Respirology, 2026. Verfasst von Tetsu Hirakawa und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutrophils, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the AMED Translational Research Grant Seeds A, Shino-Test Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Severe checkpoint inhibitor pneumonitis (CIP), particularly when it develops within 6–12 weeks, is a potentially fatal adverse event in patients with non‐small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). Although neutrophil‐to‐lymphocyte ratio (NLR) has been reported to predict immune‐related adverse events, its role in severe CIP remains unclear.

Methods

The discovery cohort retrospectively enrolled 102 patients with NSCLC treated with ICI monotherapy at Hiroshima University Hospital. The validation cohort prospectively enrolled 191 NSCLC patients receiving first‐line treatment, including ICI, at 15 institutions. Severe CIP was defined as grade 3–5 pneumonitis occurring within 3 months of treatment initiation. The cut‐off level of the baseline NLR was identified by receiver operating characteristic curve analysis in the discovery cohort, and the predictive accuracy was analyzed and confirmed in both cohorts.

Results

Severe CIP was observed in seven (6.9%) and 11 (5.8%) patients in the discovery and validation cohorts, respectively. In the discovery cohort, the baseline NLR was higher in patients with severe CIP than in those without (17.29 [4.76–20.73] vs. 3.70 [2.64–6.68], p = 0.006), and the cut‐off level of the baseline NLR was set at 4.75 (AUC 0.81; sensitivity 85.7%, specificity 64.2%). The incidence of severe CIP was significantly higher in patients with higher baseline NLR levels (≥ 4.75) than in those without, in both cohorts (discovery: 15.0% vs. 1.6%, p = 0.009; validation: 10.3% vs. 3.3%, p = 0.046).

Conclusion

Baseline NLR is a promising risk stratification marker for severe CIP. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeutrophilsImmune Checkpoint InhibitorsPneumoniaLymphocytesHumansFemaleMaleAgedRetrospective StudiesMiddle AgedProspective StudiesRisk AssessmentAged, 80 and overLymphocyte CountSeverity of Illness Index

Stichwörter der Autor:innen

biomarkercheckpoint inhibitor pneumonitisimmune checkpoint inhibitorneutrophil‐to‐lymphocyte rationon‐small‐cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Respiratory Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Respiratory Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.

ORCID-Profile: Tetsu Hirakawa, Kakuhiro Yamaguchi, Tamio Okimoto, Hisao Higo, Yoshihiro Taguchi, Kiyofumi Shimoji, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto

Förderung

  • the AMED Translational Research Grant Seeds A
  • Shino-Test Corporation

Zitieren

APA

Hirakawa, T., Yamaguchi, K., Takao, S., Kanaji, N., Matsumoto, N., Miyazaki, K., Okimoto, T., Ando, C., Higo, H., Yanai, M., Kurose, K., Nagasaki, Y., Watanabe, M., Oyama, K., Toyoda, Y., Taguchi, Y., Tada, S., Shimoji, K., Sakamoto, S., …, & Hattori, N. (2026). Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation. Respirology. https://doi.org/10.1002/resp.70267

Vancouver

Hirakawa T, Yamaguchi K, Takao S, Kanaji N, Matsumoto N, Miyazaki K, et al. Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation. Respirology. 2026. doi:10.1002/resp.70267

BibTeX
@article{Hirakawa2026,
  author = {Hirakawa, Tetsu and Yamaguchi, Kakuhiro and Takao, Shun and Kanaji, Nobuhiro and Matsumoto, Naoko and Miyazaki, Kozue and Okimoto, Tamio and Ando, Chihiro and Higo, Hisao and Yanai, Masaaki and Kurose, Koji and Nagasaki, Yasunari and Watanabe, Masako and Oyama, Kosuke and Toyoda, Yuko and Taguchi, Yoshihiro and Tada, Shimpei and Shimoji, Kiyofumi and Sakamoto, Shinjiro and Horimasu, Yasushi and Masuda, Takeshi and Nakashima, Taku and Iwamoto, Hiroshi and Hamada, Hironobu and Hattori, Noboru},
  title = {Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation},
  journal = {Respirology},
  year = {2026},
  doi = {10.1002/resp.70267}
}
Kostenlos starten →